Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
Markus Hoffmann, Heike Hofmann-Winkler, Joan C. Smith, et al.
EBioMedicine (2021) Vol. 65, pp. 103255-103255
Open Access | Times Cited: 329

Showing 1-25 of 329 citing articles:

SARS-CoV-2 pathogenesis
Mart M. Lamers, Bart L. Haagmans
Nature Reviews Microbiology (2022) Vol. 20, Iss. 5, pp. 270-284
Open Access | Times Cited: 712
Structural biology of SARS-CoV-2: open the door for novel therapies
Weizhu Yan, Yanhui Zheng, Xiao‐Tao Zeng, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 249
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, et al.
Cell Reports (2021) Vol. 36, Iss. 3, pp. 109415-109415
Open Access | Times Cited: 233
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
Tirosh Shapira, I. Abrrey Monreal, Sébastien P. Dion, et al.
Nature (2022) Vol. 605, Iss. 7909, pp. 340-348
Open Access | Times Cited: 181
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
Jesper Damsgaard Gunst, Nina Breinholt Stærke, Marie H. Pahus, et al.
EClinicalMedicine (2021) Vol. 35, pp. 100849-100849
Open Access | Times Cited: 173
Proteolytic activation of SARS‐CoV‐2 spike protein
Makoto Takeda
Microbiology and Immunology (2021) Vol. 66, Iss. 1, pp. 15-23
Open Access | Times Cited: 172
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
Fiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, et al.
PLoS Medicine (2021) Vol. 18, Iss. 7, pp. e1003656-e1003656
Open Access | Times Cited: 143
Drug repurposing for COVID-19: Approaches, challenges and promising candidates
Yan Ling Ng, Cyrill Kafi Salim, Justin Jang Hann Chu
Pharmacology & Therapeutics (2021) Vol. 228, pp. 107930-107930
Open Access | Times Cited: 135
Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)
Edina Cenko, Lina Badimón, Raffaele Bugiardini, et al.
Cardiovascular Research (2021) Vol. 117, Iss. 14, pp. 2705-2729
Open Access | Times Cited: 131
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
Kun Li, David K. Meyerholz, Jennifer A. Bartlett, et al.
mBio (2021) Vol. 12, Iss. 4
Open Access | Times Cited: 128
The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways
Manon Laporte, Valerie Raeymaekers, Ria Van Berwaer, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 4, pp. e1009500-e1009500
Open Access | Times Cited: 119
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 118
The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients
G. S. Gupta
Inflammation (2022) Vol. 45, Iss. 6, pp. 2091-2123
Open Access | Times Cited: 86
Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
Bingjie Hu, Jasper Fuk‐Woo Chan, Huan Liu, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2275-2287
Open Access | Times Cited: 72
TMPRSS2 is a functional receptor for human coronavirus HKU1
Nell Saunders, I. Fernández, Cyril Planchais, et al.
Nature (2023) Vol. 624, Iss. 7990, pp. 207-214
Open Access | Times Cited: 62
TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection
Kristin Metzdorf, Henning Jacobsen, Marina C. Greweling‐Pils, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 271-271
Open Access | Times Cited: 47
COVID-19 drug discovery and treatment options
Jasper Fuk‐Woo Chan, Shuofeng Yuan, Hin Chu, et al.
Nature Reviews Microbiology (2024) Vol. 22, Iss. 7, pp. 391-407
Closed Access | Times Cited: 21
Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection
Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit
PLoS Computational Biology (2020) Vol. 16, Iss. 12, pp. e1008461-e1008461
Open Access | Times Cited: 136
Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety
Peter Breining, Anne Lier Frølund, Jesper Falkesgaard Højen, et al.
Basic & Clinical Pharmacology & Toxicology (2020) Vol. 128, Iss. 2, pp. 204-212
Open Access | Times Cited: 129
An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19
Jonathan H. Shrimp, Stephen C. Kales, Philip E.J. Sanderson, et al.
ACS Pharmacology & Translational Science (2020) Vol. 3, Iss. 5, pp. 997-1007
Open Access | Times Cited: 126
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
Matthew Mahoney, Vishnu C. Damalanka, Michael A. Tartell, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 43
Open Access | Times Cited: 97
Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
Tim Hempel, Lluı́s Raich, Simon Olsson, et al.
Chemical Science (2020) Vol. 12, Iss. 3, pp. 983-992
Open Access | Times Cited: 96
COVID-19, cytokines, inflammation, and spices: How are they related?
Ajaikumar B. Kunnumakkara, Varsha Rana, Parama Dey, et al.
Life Sciences (2021) Vol. 284, pp. 119201-119201
Open Access | Times Cited: 96
Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19
Qu Deng, Reyaz ur Rasool, Ronnie M. Russell, et al.
iScience (2021) Vol. 24, Iss. 3, pp. 102254-102254
Open Access | Times Cited: 92
SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination
Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 90
Page 1 - Next Page

Scroll to top